These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 7591264)
1. Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Hills D; Rowlinson-Busza G; Gullick WJ Int J Cancer; 1995 Nov; 63(4):537-43. PubMed ID: 7591264 [TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Okamoto S; Yoshikawa K; Obata Y; Shibuya M; Aoki S; Yoshida J; Takahashi T Br J Cancer; 1996 Jun; 73(11):1366-72. PubMed ID: 8645581 [TBL] [Abstract][Full Text] [Related]
3. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Nishikawa R; Ji XD; Harmon RC; Lazar CS; Gill GN; Cavenee WK; Huang HJ Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7727-31. PubMed ID: 8052651 [TBL] [Abstract][Full Text] [Related]
4. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. Huang HS; Nagane M; Klingbeil CK; Lin H; Nishikawa R; Ji XD; Huang CM; Gill GN; Wiley HS; Cavenee WK J Biol Chem; 1997 Jan; 272(5):2927-35. PubMed ID: 9006938 [TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Binder ZA; Thorne AH; Bakas S; Wileyto EP; Bilello M; Akbari H; Rathore S; Ha SM; Zhang L; Ferguson CJ; Dahiya S; Bi WL; Reardon DA; Idbaih A; Felsberg J; Hentschel B; Weller M; Bagley SJ; Morrissette JJD; Nasrallah MP; Ma J; Zanca C; Scott AM; Orellana L; Davatzikos C; Furnari FB; O'Rourke DM Cancer Cell; 2018 Jul; 34(1):163-177.e7. PubMed ID: 29990498 [TBL] [Abstract][Full Text] [Related]
6. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Humphrey PA; Wong AJ; Vogelstein B; Zalutsky MR; Fuller GN; Archer GE; Friedman HS; Kwatra MM; Bigner SH; Bigner DD Proc Natl Acad Sci U S A; 1990 Jun; 87(11):4207-11. PubMed ID: 1693434 [TBL] [Abstract][Full Text] [Related]
7. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591 [TBL] [Abstract][Full Text] [Related]
8. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts. Liu X; Dong C; Shi J; Ma T; Jin Z; Jia B; Liu Z; Shen L; Wang F Oncotarget; 2017 Jan; 8(4):6364-6375. PubMed ID: 28031526 [TBL] [Abstract][Full Text] [Related]
9. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Eller JL; Longo SL; Hicklin DJ; Canute GW Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411 [TBL] [Abstract][Full Text] [Related]
10. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Clarke K; Smith K; Gullick WJ; Harris AL Br J Cancer; 2001 May; 84(10):1322-9. PubMed ID: 11355942 [TBL] [Abstract][Full Text] [Related]
11. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. Gan HK; Lappas M; Cao DX; Cvrljevdic A; Scott AM; Johns TG J Cell Mol Med; 2009 Sep; 13(9B):3993-4001. PubMed ID: 19432811 [TBL] [Abstract][Full Text] [Related]
12. Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor. Nakayashiki N; Yoshikawa K; Nakamura K; Hanai N; Okamoto K; Okamoto S; Mizuno M; Wakabayashi T; Saga S; Yoshida J; Takahashi T Jpn J Cancer Res; 2000 Oct; 91(10):1035-43. PubMed ID: 11050475 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Harwerth IM; Wels W; Schlegel J; Müller M; Hynes NE Br J Cancer; 1993 Dec; 68(6):1140-5. PubMed ID: 7903153 [TBL] [Abstract][Full Text] [Related]
14. Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain. Ozer BH; Wiepz GJ; Bertics PJ Oncogene; 2010 Feb; 29(6):855-64. PubMed ID: 19915609 [TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735 [TBL] [Abstract][Full Text] [Related]
16. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Panousis C; Rayzman VM; Johns TG; Renner C; Liu Z; Cartwright G; Lee FT; Wang D; Gan H; Cao D; Kypridis A; Smyth FE; Brechbiel MW; Burgess AW; Old LJ; Scott AM Br J Cancer; 2005 Mar; 92(6):1069-77. PubMed ID: 15770208 [TBL] [Abstract][Full Text] [Related]
17. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Humphrey PA; Gangarosa LM; Wong AJ; Archer GE; Lund-Johansen M; Bjerkvig R; Laerum OD; Friedman HS; Bigner DD Biochem Biophys Res Commun; 1991 Aug; 178(3):1413-20. PubMed ID: 1678600 [TBL] [Abstract][Full Text] [Related]
18. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Modjtahedi H; Styles JM; Dean CJ Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290 [TBL] [Abstract][Full Text] [Related]
19. RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells. Martínez-Lacaci I; Kannan S; De Santis M; Bianco C; Kim N; Wallace-Jones B; Ebert AD; Wechselberger C; Salomon DS Int J Cancer; 2000 Oct; 88(1):44-52. PubMed ID: 10962438 [TBL] [Abstract][Full Text] [Related]
20. Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin. Schmidt M; Reiser P; Hills D; Gullick WJ; Wels W Int J Cancer; 1998 Mar; 75(6):878-84. PubMed ID: 9506533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]